| Name | Title | Contact Details |
|---|
We are on the leading edge of research, development, clinical trials, and implementation of digital solutions that are aimed at harm reduction for various public health challenges. Our goal is to reduce harm and prevent unintentional deaths for people of all ages. Our team has pioneered apps that were developed in response to the opioid crisis, which is now a world-wide problem, as well as the COVID-19 pandemic and health & safety concerns in senior care centers.
Good Samaritan Lutheran Health is a Delmar, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
At Tegria, we believe that the right technology and tools can help make care more effective for more people. Launched in 2020 with support from Providence, one of the country`s largest health systems, Tegria combines innovative technologies and services to create powerful solutions that simplify healthcare for everyone involved. We built Tegria to make a difference, not only for our customers, but for our communities. We deliver complete solutions to streamline the process of receiving and delivering care, from first visit to follow-up and beyond.
Radiant Health is a functional medicine practice that focuses on empowering and inspiring women to reclaim their health by addressing the root cause of symptoms or disease and creating personalized lifestyle plans to achieve vitality and wellness.
At PanOptica, our aim is to develop new ocular therapies that help patients see their very best throughout their lives. Many patients with common eye diseases suffer debilitating vision loss, despite currently available treatments. At PanOptica, we understand the critical role vision plays in a patient`s quality of life. And we know the frustration eye care professionals face when they are unable to treat their patients successfully. Today, significant progress is being made in the field of ophthalmology, with small laboratories and large pharmaceutical companies alike exploring newer, more effective treatments for sight-threatening diseases. PanOptica seeks to license and develop these innovative therapeutics, which may include improvements to existing therapies or entirely new treatments for previously untreatable disorders. Our lead development compound, PAN-90806 , is a novel, small-molecule selective VEGF receptor antagonist that shows promise as a topical treatment for wet age-related macular degeneration and diabetic retinopathy.